Company
We are an innovation-driven biopharmaceutical company headquartered in China with a
global vision, dedicated to discovering and developing small-molecule backbone therapies for
oncology and immunology indications. Enabled by our integrated Small Molecule Backbone Drug
R&D Platform and strategically guided by clinical practice guidelines,
we focus on advancing novel backbone small molecule therapies with synergistic mechanisms to
existing standards of care, aiming to develop globally IP protected innovative medicines that are
differentiated, clinically meaningful and accessible to patients worldwide.
Established in March 2016 by Dr. Yuguang Wang, a globally recognized scientist with over 30 years of experience in pharmaceutical R&D, we have built a pipeline of six drug candidates, including three clinical-stage programs, aimed at addressing significant unmet medical needs in oncology, with indications covering acute myeloid leukemia (AML), glioma, nasopharyngeal carcinoma, and other solid tumors, as backbone therapies that can be safely, efficiently, and broadly integrated into existing standards of care.
Description
MaxiNovel: Pioneer of Cornerstone Small Molecule Medicines
